|
07 Jun 2026 |
Inventurus Knowledge
|
Consensus Share Price Target
|
1659.10 |
1886.63 |
- |
13.71 |
buy
|
|
|
|
|
26 Apr 2026
|
Inventurus Knowledge
|
Motilal Oswal
|
1659.10
|
1902.00
|
1438.00
(15.38%)
|
14.64 |
Buy
|
|
|
IKS announced the acquisition of TruBridge, a leading healthcare IT and RCM services provider in the US, with revenue of USD347m in CY25, almost equal to IKS’s revenue base.
|
|
05 Feb 2026
|
Inventurus Knowledge
|
Motilal Oswal
|
1659.10
|
2109.00
|
1703.70
(-2.62%)
|
27.12 |
Buy
|
|
|
IKS’s 3QFY26 USD revenue rose 19% YoY to USD93m, led by strong performance from top clients and healthy contribution from new deals and partnerships.
|
|
12 Nov 2025
|
Inventurus Knowledge
|
ICICI Securities Limited
|
1659.10
|
2000.00
|
1644.70
(0.88%)
|
20.55 |
Buy
|
|
|
We met IKS’ management at I-Sec conference. IKS is focusing on continuing the traction on full-platform deals, increasing cross-selling with AQuity clients, using AI to gain operating margin leverage and increase non-linearity between revenue and headcount growth and working with hospitals.
|
|
10 Mar 2025
|
Inventurus Knowledge
|
ICICI Securities Limited
|
1659.10
|
1820.00
|
1732.15
(-4.22%)
|
Target met |
Hold
|
|
|
IKS Health (IKS) is a Platform as a Service (PaaS) company that caters to US’ healthcare provider segment. It focusses on outsourcing the routine chores of physicians. IKS’ platform has 16 key features, spanning across chores in a physician’s value chain, bundled into admin offerings and clinical offerings.
|
|
12 Dec 2024
|
Inventurus Knowledge
|
Ashika Research
|
1659.10
|
|
|
|
IPO Note
|
|
|
|
|
11 Dec 2024
|
Inventurus Knowledge
|
SBI Securities
|
1659.10
|
|
|
|
IPO Subscribe
|
|
|
|
|
10 Dec 2024
|
Inventurus Knowledge
|
Ventura
|
1659.10
|
|
|
|
IPO Subscribe
|
|
|
|